The two kinds of IL-23-expressing viruses elicited similar therapeutic effects on two subcutaneous tumor models, but vvDD-IL-23-FG elicited weaker antitumor effects on the intraperitoneal MC38 tumor model, though this difference is not statistically significant. This evidence concerns the gene IL23A and neoplasm.